Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder.
| Webinar: | “XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs” |
| Date: | Tuesday, September 19, 2023 |
| Time: | 11:30 am – 1 pm ET Eastern Time (8:30 am – 11 am Pacific Time) |
| Link: | Participants can register and access the webinar on the Investors section of Xenon’s website. |
| Format: | Questions may be submitted (via chat function) during the live webinar or submitted in advance via email. |
Speakers include:
A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…
Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…
Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…
Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…
LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…